150 related articles for article (PubMed ID: 31383643)
41. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.
Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK;
Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913
[TBL] [Abstract][Full Text] [Related]
42. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood.
Jiang NG; Jin YM; Niu Q; Zeng TT; Su J; Zhu HL
Ann Hematol; 2013 Jan; 92(1):89-96. PubMed ID: 22992980
[TBL] [Abstract][Full Text] [Related]
43. Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.
Margolskee E; Jobanputra V; Jain P; Chen J; Ganapathi K; Nahum O; Levy B; Morscio J; Murty V; Tousseyn T; Alobeid B; Mansukhani M; Bhagat G
Oncotarget; 2016 Jun; 7(25):37636-37648. PubMed ID: 27203213
[TBL] [Abstract][Full Text] [Related]
44. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.
Chang CW; Lai YS; Westin E; Khodadadi-Jamayran A; Pawlik KM; Lamb LS; Goldman FD; Townes TM
Cell Rep; 2015 Sep; 12(10):1668-77. PubMed ID: 26321643
[TBL] [Abstract][Full Text] [Related]
45. CCL22 Mutations Promote NK-cell Lymphoproliferative Disease.
Cancer Discov; 2022 Jul; 12(7):OF17. PubMed ID: 35554510
[TBL] [Abstract][Full Text] [Related]
46. Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
Menter T; Juskevicius D; Alikian M; Steiger J; Dirnhofer S; Tzankov A; Naresh KN
Br J Haematol; 2017 Jul; 178(1):48-56. PubMed ID: 28419429
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis.
Mitarnun W; Suwiwat S; Pradutkanchana J; Saechan V; Ishida T; Takao S; Mori A
Am J Hematol; 2002 May; 70(1):31-8. PubMed ID: 11994979
[TBL] [Abstract][Full Text] [Related]
48. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
[No Abstract] [Full Text] [Related]
49. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions.
Zhang Y; Nagata H; Ikeuchi T; Mukai H; Oyoshi MK; Demachi A; Morio T; Wakiguchi H; Kimura N; Shimizu N; Yamamoto K
Br J Haematol; 2003 Jun; 121(5):805-14. PubMed ID: 12780797
[TBL] [Abstract][Full Text] [Related]
50. [EB virus-positive T/NK lymphoproliferative diseases: an analysis of 156 patients].
Zhang YL; Xie JL; Zheng YY; Wei P; Huang YH; Zheng XD; Teng XJ; Liu W; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):407-411. PubMed ID: 29886582
[No Abstract] [Full Text] [Related]
51. [CD16+ CD56- indolent, NK cell-lineage granular lymphocyte proliferative disorder with autoimmune hemolytic anemia].
Tomita N; Motomura S; Takemura S; Fujimaki K; Sakai R; Harano H; Ishigatsubo Y
Rinsho Ketsueki; 2000 Mar; 41(3):225-8. PubMed ID: 10774253
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications.
Paik JH; Choe JY; Kim H; Lee JO; Kang HJ; Shin HY; Lee DS; Heo DS; Kim CW; Cho KH; Kim TM; Jeon YK
Leuk Lymphoma; 2017 Jan; 58(1):53-63. PubMed ID: 27157296
[TBL] [Abstract][Full Text] [Related]
53. JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.
Di Matteo G; Chiriaco M; Scarselli A; Cifaldi C; Livadiotti S; Di Cesare S; Ferradini V; Aiuti A; Rossi P; Finocchi A; Cancrini C
Mol Genet Genomic Med; 2018 Sep; 6(5):713-721. PubMed ID: 30032486
[TBL] [Abstract][Full Text] [Related]
54. Oral manifestation of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract: A potential diagnostic pitfall.
Saggini A; Baciorri F; Di Prete M; Zizzari AG; Anemona L
J Cutan Pathol; 2020 May; 47(5):494-496. PubMed ID: 32003865
[No Abstract] [Full Text] [Related]
55. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.
Montes-Moreno S; King RL; Oschlies I; Ponzoni M; Goodlad JR; Dotlic S; Traverse-Glehen A; Ott G; Ferry JA; Calaminici M
Virchows Arch; 2020 May; 476(5):667-681. PubMed ID: 31773249
[TBL] [Abstract][Full Text] [Related]
56. Rapid protein-based assays for the diagnosis of T-B+ severe combined immunodeficiency.
Gilmour KC; Cranston T; Loughlin S; Gwyther J; Lester T; Espanol T; Hernandez M; Savoldi G; Davies EG; Abinun M; Kinnon C; Jones A; Gaspar HB
Br J Haematol; 2001 Mar; 112(3):671-6. PubMed ID: 11260071
[TBL] [Abstract][Full Text] [Related]
57. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders.
Morice WG
Am J Clin Pathol; 2007 Jun; 127(6):881-6. PubMed ID: 17509985
[TBL] [Abstract][Full Text] [Related]
58. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
59. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
[TBL] [Abstract][Full Text] [Related]
60. JAK and MPL mutations in myeloid malignancies.
Tefferi A
Leuk Lymphoma; 2008 Mar; 49(3):388-97. PubMed ID: 18297515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
